Switzerland
- Latest Posts
BIO-Europe Spring 2023: The Highlights
BIO-Europe Spring is one of Europe’s biggest biotech partnering events with discussion topics ranging from platform technologies and manufacturing to biotech investments. Here are some of the key take-home reports from the proceedings. The event, which took place from March 20 to 22, in the budding biotech hub of Basel, Switzerland, was in full swing […]
Pharma services companies you should know about at Bio-Europe Spring 2023
Bio-Europe Spring 2023, which takes place March 20-22 in Basel, Switzerland, is the largest gathering of biopharma professionals in Europe. It presents an opportunity for companies from around the world to engage in face-to-face meetings and facilitate partnerships. Alongside networking, there will also be workshops, panels, exhibitions, and a variety of company presentations. The keynote […]
News and Trends 8 Mar 2023
Noema Pharma raises $112 million in Series B financing
Noema Pharma, a Swiss clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, has closed an oversubscribed Series B financing round, raising CHF 103 million ($112 million) from new and existing investors. The round was co-led by leading European healthcare focused investment firms Forbion and Jeito Capital. UPMC Enterprises and an additional new investor […]
Basel: It Takes an Ecosystem to Build a Startup
Europe has a number of bubbling biotech hubs that offer access to expertise, financial support, and networking opportunities for young healthcare ventures. One of them is the Basel Area in Switzerland. It goes without saying that the basis of each biotech should always be world-class innovation. But that is just the beginning: In order to […]
News and Trends 3 Mar 2023
Debiopharm adds to oncology pipeline
Debiopharm, an independent Swiss-based, biopharmaceutical company, has obtained the global rights for FT-3171, a small molecule USP1 inhibitor program targeting a novel DNA damage repair (DDR) pathway from Novo Nordisk. FT-3171 was developed by Forma Therapeutics, which was acquired by Novo Nordisk in 2022, and is currently in late preclinical development. FT-3171 (Debio 0432) could […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 3 Mar 2023
Orphan drug designation for Laevoroc metabolic immune checkpoint inhibitor
Laevoroc Immunology, a privately-owned, Swiss oncology development company, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for immune checkpoint inhibitor LR 09. LR 09 is a novel metabolic immune checkpoint inhibitor, for the treatment of patients with hematological malignancies who are diagnosed with a relapse after allogeneic stem […]
News and Trends 7 Feb 2023
Harvard spin-off cellvie closes $5.5M new funding
cellvie Inc., which works on therapeutic mitochondria transplantation (TMT), an approach developed at Harvard Medical School, has closed a $5.5 million financing to get Series A-ready by the end of 2023. Mitochondria dysfunction has been tied to a host of diseases, ranging from neurodegenerative ailments, heart attacks and strokes, to age-related degeneration. “Whilst mitochondria have […]
News and Trends 3 Feb 2023
AI boosts genome editing
Researchers at the University of Zurich have developed a new tool that uses artificial intelligence to predict the efficacy of various genome-editing repair options. Unintentional errors in the correction of DNA mutations of genetic diseases can thus be reduced. Genome editing technologies offer great opportunities for treating genetic diseases. Methods such as the widely used […]
Best in Biotech 31 Jan 2023
13 biotech companies to discover in the Swiss Health Valley in 2023
We recently featured BioAlps on the Beyond Biotech Podcast. While Basel is certainly a European biotech hotspot, it’s not the only one in Switzerland. The Health Valley covering the western part of Switzerland has plenty of biotech companies in and around Lake Geneva (also known as Lac Leman), in the cities of Geneva and in […]
News and Trends 20 Jan 2023
Beyond Biotech podcast 30: Advanced Therapies Congress, BioAlps, Bionter, C2i Genomics
The guests on our podcast this week are: Jessica Robinson, project director, Advanced Therapies Congress, Terrapinn: Tobias Werk, CEO, Bionter; Asaf Zviran, CEO and co-founder of C2i Genomics; and Magali Bischof, secretary general of BioAlps. We also have our weekly commentary from Travis McCready at global commercial real estate services company JLL. This week’s podcast […]
In Depth 17 Jan 2023
Cell and gene therapies gain momentum in Basel
Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the globe, and a growing number are choosing the Swiss city of Basel as their base. These companies are taking advantage of the talent pool, academic institutions and investors that the area has to offer, culturing […]
ADVERTISEMENT